Respiratory Diagnostics Market

Respiratory Diagnostics Market Size by Product & Services (Devices, Reagents, Software), Test (PFT, Peak Flow, Spirometry), OSA, Imaging (X-ray, CT, MRI, PET), Molecular (PCR, DNA Sequencing), Indication (Lung Cancer, Asthma, COPD, TB) & Region - Global Forecast to 2029

Report Code: MD 4740 Nov, 2023, by marketsandmarkets.com

The global size of respiratory diagnostics market in terms of revenue was estimated to be worth $5.6 billion in 2023 and is poised to reach $8.2 billion by 2029, growing at a CAGR of 6.6% from 2023 to 2029. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.

Growth in this market is largely driven by the growth in the large patient population suffering from pulmonary diseases, increase in pre-term deliveries, rise in adults being exposed to poor air quality index environment, increased smoking of tobacco, increased cases of passive smoking due to exposure to harmful smoke inhalations, rise in dust and allergies associated with it leading to asthma and COPD, rising R&D expenditure by leaders in this market, increased trend of smoking in women more than men, and massive rise in underlying lung diseases, and continuous exposure to indoor or outdoor dust, making it prone to infections, leading the market growth.

Attractive Opportunities in Respiratory diagnostics market

Respiratory diagnostics market

To know about the assumptions considered for the study, Request for Free Sample Report

Respiratory diagnostics market

Respiratory Diagnostics Market Dynamics

Driver: High prevalence of tobacco smoking

Smoking is the leading cause of COPD. According to WHO, tobacco kills up to half of its users and over 80% of the world's 1.3 billion tobacco users, who live in low- and middle-income countries. Furthermore, as per the Centers for Disease Control and Prevention (CDC), cigarette smoking remains the leading cause of preventable diseases, disabilities, and deaths in the US, accounting for over 480,000 deaths annually, including more than 41,000 deaths from secondhand smoke exposure. Another 16 million live with a serious illness such as lung cancer, COPD, and respiratory infections caused by smoking. Each year, the US spends more than USD 225 billion on medical care to treat smoking-related diseases in adults. Studies suggest that 12% of the US adults smoke cigarettes in 2023 as compared to 11% in 2022. Adults of the age of 18 to 29 years, smoke e-cigarettes. Thus, it is expected to boost the market.

Restraint: Unfavorable reimbursement scenario

Patient needs to pay out of their pockets for most tests due to the increased testing capabilities and reduced reimbursement received by insurance players. Reimbursement is mainly influenced by the test type and payers fee structure. The cost of complete diagnostic testing like respiratory analysis, sleep analysis, mechanical tests, PCR test kits, etc., is partially reimbursed by insurance payers such as that of Medicare and Medicaid.

A decline in insurance claims if about 5% to 10% is a nominal range for the insurer. Mainly, the severity of the disease and criticality are majorly responsible for determining the claims rate.  Medicare payment amounts for CPT 95806 (unattended, simultaneous recording of sleep study, oxygen saturation, respiratory airflow, heart rate and respiratory effort, and thoracoabdominal movement) continue with a 15% decrease in global service payment from the previous year. The difference between the two codes is that CPT 95800 may include the use of Peripheral Arterial Tone technology and the requirement for the measurement of sleep time by the devices.

Opportunity: Growing awareness about ill effects of untreated sleep apnea

Globally, many countries are becoming increasingly conscious of the economic impact of untreated sleep apnea. In the US, the total economic cost of insufficient sleep is USD 43–46 billion, while undiagnosed moderate to severe sleep apnea in middle-aged adults may cause USD 3.4 billion in additional medical costs (Source: ResMed). The estimated financial burden of OSA (including healthcare costs, lost productivity, and road and work-related accidents) in Australia is in the range of USD 2 to 8 billion per year (Source: Snore Australia).

Obstructive sleep apnea poses a significant threat to heart health, with potential long-term consequences extending to various related ailments such as cardiovascular disease, congestive heart failure, type 2 diabetes, stroke, and other sleep disturbances. Additionally, cognitive and memory impairments can result from undiagnosed sleep apnea, impacting not only a person's health but also their career, financial stability, and overall well-being. According to ResMed, individuals with obstructive sleep apnea face a 140% higher risk of heart failure, a 60% increased risk of stroke, and a 30% elevated risk of coronary heart disease. Remarkably, up to 83% of patients with type 2 diabetes may have undetected sleep apnea.

The severity of these cognitive diseases emphasizes the importance of early diagnosis, as it can significantly influence various aspects of an individual's life. Fortunately, government initiatives, healthcare campaigns, and check-up camps are creating ample opportunities for the detection of such insidious diseases. These efforts contribute to an expanding market space, allowing for increased awareness, diagnosis, and intervention in the realm of obstructive sleep apnea and its associated health risks.

Challenge: Low awareness and lack of diagnosis of respiratory diseases

 Despite their high prevalence, major respiratory diseases such as asthma and COPD are significantly underdiagnosed and undertreated, particularly in developing economies. This is primarily attributed to the low awareness surrounding these conditions and the insufficient availability of resources for accurate diagnosis. According to the World Health Organization (WHO), over 90% of COPD deaths and 80% of asthma-related deaths occur in low- and middle-income countries.

COPD, a leading cause of global morbidity and mortality, poses a significant diagnostic challenge. Community-based studies across continents, including Europe, Australia, North and South America, and Asia, indicate that approximately 10 to 12% of adults aged 40 years or older exhibit persistent airflow limitation on spirometry. However, only 20 to 30% of these individuals receive a formal COPD diagnosis. In the United States alone, nearly 16 million adults succumb to COPD-related deaths without a prior diagnosis.

The lack of awareness and a substantial undiagnosed population pose significant challenges to the respiratory diagnostics market, hindering its potential for addressing and mitigating the impact of these respiratory diseases on global health.

Respiratory Diagnostics Market Ecosystem

Leading players in this market include well-established and financially stable service providers of respiratory diagnostic. These companies have been operating in the market for several years and possess a diversified product portfolio, advanced technologies, and strong global presence. Prominent companies in this market include Koninklijke Philips N.V(Netherlands), BD (US), Abbott (US), Thermo Fisher Scientific Inc(US), GE HealthCare (US), Bio-Rad Laboratories, Inc. (US), BioMérieux (France), RevvityInc(US), Seegene Inc(South Korea), Nihon Kohden Corporation (Japan), Vitalograph (UK), SDI Diagnostics (US), ResMed Inc(US), Siemens Healthcare GmbH (Germany), Cosmed (Italy)Hologic, Inc(US), and Qiagen (Netherland).

Respiratory diagnostics market Ecosystem

The assays and reagents segment of the respiratory diagnostics industry accounted for the highest CAGR in of the product and services segment.

By products and services, the respiratory diagnostics market is segmented into instruments and devices, assays and reagents, and services and software. The assays and reagents accounted for the highest share due to the increased demand for improved and potent assay reagents, growing manufacturing units developing such consumables, and increased number of sample sizes. Assays and reagents are one-time use consumables, thus, their reduced shelf life is also a major reason for his high growth in this market.

The COPD segment of the respiratory diagnostics industry is estimated to grow at a higher CAGR during the forecast period.

Based on disease indication, the respiratory diagnostics market is segmented into chronic obstructive pulmonary disease (COPD), asthma, tuberculosis, lung cancer, and other disease indications The COPD segment is estimated to grow at a higher CAGR during the forecast period. Rise in smoking culture among young adults, exposure to chemical dusts, increased allergy to pollens in growing adults in developed countries, and increase in declined air quality mainly in emerging nations.

One of the major causes of COPD is tobacco smoking. According to the US Centers for Disease Control and Prevention (CDC), as many as 8 in 10 COPD-related deaths are due to smoking. Additionally, rising indoor and outdoor air pollution levels, exposure to dust and chemicals are other factors driving the prevalence of COPD.

The hospital settings segment of the respiratory diagnostics industry is expected to grow at the highest CAGR during the forecast period.

The respiratory diagnostics market is segmented into hospital, diagnostic laboratories, and others like universities, research institutions, and smaller study centers. The hospital region accounted for the highest CAGR mainly due to the large number of of admissions for respiratory diseases, increased advantage of in house testing capabilities, rise in pulmonary diseases and severity of the same, and availability of early diagnostic results and care under the same roof is the primary contributor to the growth of this market segment.

APAC is estimated to be the fastest-growing regional market for respiratory diagnostics industry.

The global respiratory diagnostics market is segmented into Asia Pacific, North America, Europe, Latin America, and the Middle East & Africa. In 2022, APAC is estimated to be the fastest-growing regional market for respiratory diagnostics market. Gradual increase in healthcare expenditure in emerging countries of Asia Pacific region, growth in medical tourism, low diagnostic testing cost due to increased number of diagnostic labs and increase in manufacturers, are the factors for the growth of Asia Pacific region.

Respiratory diagnostics market by Region

To know about the assumptions considered for the study, download the pdf brochure

The prominent players in the respiratory diagnostics market are Koninklijke Philips N.V. (Netherlands), BD (US), Abbott (US), Thermo Fisher Scientific Inc (US), GE HealthCare (US) , Bio-Rad Laboratories Inc. (US), BioMérieux (France), RevvityInc(US), Seegene Inc(South Korea), Nihon Kohden Corporation (Japan), Vitalograph (UK), SDI Diagnostics (US), ResMed Inc(US), Siemens Healthcare GmbH (Germany), Cosmed (Italy)Hologic, Inc(US), Qiagen (Netherlands), Vyaire (US), Visby Medical Inc (US), Briota Technologies Private Limited (India), Bird Healthcare (Australia), Löwenstein Medical Technology (Germany), ProAxsis (Northern Ireland), ndd Medical Technologies (US) and Compumedics Limited (Australia). Major players adopt growth strategies to expand their geographical presence and garner higher shares in the global market.

Scope of the Respiratory Diagnostics Industry

Report Metric

Details

Market Revenue in 2023

$5.6 billion

Projected Revenue by 2028

$8.2 billion

Revenue Rate

Poised to Grow at a CAGR of 6.6%

Market Driver

High prevalence of tobacco smoking

Market Opportunity

Growing awareness about ill effects of untreated sleep apnea

The research report categorizes respiratory diagnostics market to forecast revenue and analyze trends in each of the following submarkets:

By Product and Service

  • Instruments & Devices
  • Assays & Reagents
  • Services & Software

By Test Type

  • Mechanical Tests
    • Pulmonary Function Tests
    • Spirometry
    • Peak Flow Test
  • Osa Diagnostic Tests
  • Imaging Tests
    • X-Ray
    • Computed Tomography
    • Magnetic Resonance Imaging (MRI)
    • Positron Emission Tomography (PET)
    • Other Imaging Tests
  • Traditional Diagnostic Tests
    • Immunodiagnostics
    • Biochemical Tests
    • Microscopy
  • Molecular Diagnostic Tests
    • PCR
    • Nucleic Acid Amplification Test
    • In Situ Hybridization
    • Dna Sequencing & Next-Generation Sequencing (NGS)
    • Microarrays
    • Others

By Technology Level

  • Basic Equipment
  • Advanced Equipment
  • Cutting Edge Equipment

By Disease Indication

  • Tuberculosis
  • Asthma
  • Lung Cancer
  • Chronic Obstructive Pulmonary Disease
  • Others

By End User

  • Hospitals and Clinics
  • Diagnostics Laboratories
  • Others

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Australia
    • Japan
    • India
    • Australia
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East and Africa

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

INTRODUCTION
29
RESEARCH METHODOLOGY
35
EXECUTIVE SUMMARY
50
PREMIUM INSIGHTS
54
MARKET OVERVIEW
57
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Rising prevalence of respiratory diseases
    - Increasing rate of preterm births
    - Increasing outbreaks of infectious diseases affecting respiratory system
    - Growing population with sleep disorders
    - Rising R&D investments for technologically advanced medical devices
    RESTRAINTS
    - Unfavorable reimbursement policies
    - Availability of low-cost products from local manufacturers
    OPPORTUNITIES
    - Increased market growth in Asia Pacific and Latin America
    - Improving POC diagnostics
    - Increasing ill effects of untreated sleep apnea
    CHALLENGES
    - Low awareness and lack of diagnosis of respiratory diseases
  • 5.3 INDUSTRY TRENDS
    RISING DEMAND FOR POINT-OF-CARE DIAGNOSTIC DEVICES
    FOCUS OF MARKET PLAYERS ON GEOGRAPHICAL EXPANSIONS
    INCREASING NUMBER OF REAGENT RENTAL AGREEMENTS
  • 5.4 SUPPLY CHAIN ANALYSIS
  • 5.5 TARIFF AND REGULATORY ANALYSIS
    REGULATORY ANALYSIS
    - North America
    - Europe
    - Asia Pacific
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    - North America
    - Europe
    - Rest of the World
  • 5.6 ECOSYSTEM MARKET MAP
  • 5.7 VALUE CHAIN ANALYSIS
  • 5.8 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - Digitalization of diagnostic tests
    ADJACENT TECHNOLOGIES
    - Rapid respiratory diagnostic kits
    COMPLEMENTARY TECHNOLOGIES
  • 5.9 PATENT ANALYSIS
    PATENT PUBLICATION TRENDS
    JURISDICTION AND TOP APPLICANT ANALYSIS
  • 5.10 TRADE ANALYSIS
  • 5.11 CASE STUDY ANALYSIS
  • 5.12 PORTER’S FIVE FORCES ANALYSIS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.13 KEY CONFERENCES & EVENTS
  • 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    BUYING CRITERIA
  • 5.15 PRICING ANALYSIS
    AVERAGE SELLING PRICE TREND, BY REGION
  • 5.16 ADJACENT MARKETS
  • 5.17 UNMET NEEDS IN RESPIRATORY DIAGNOSTIC DEVICES
  • 5.18 USE OF ARTIFICIAL INTELLIGENCE IN RESPIRATORY DIAGNOSTICS MARKET
    USE OF BIG DATA AND ARTIFICIAL INTELLIGENCE IN HEALTHCARE
  • 5.19 REIMBURSEMENT SCENARIO ANALYSIS
RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE
95
  • 6.1 INTRODUCTION
  • 6.2 INSTRUMENTS AND DEVICES
    INCREASING PREVALENCE OF RESPIRATORY DISEASES TO DRIVE MARKET
  • 6.3 ASSAYS AND REAGENTS
    RISING DEMAND FOR RESPIRATORY DIAGNOSTIC TEST KITS TO DRIVE MARKET
  • 6.4 SERVICES AND SOFTWARE
    INTRODUCTION TO ADVANCED AND AUTOMATED TECHNOLOGIES TO DRIVE MARKET
RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE
100
  • 7.1 INTRODUCTION
  • 7.2 MECHANICAL TESTS
    PULMONARY FUNCTION TESTS
    SPIROMETRY
    - Spirometry to dominate pulmonary function tests segment during forecast period
    PEAK FLOW TESTS
    - Precise measurements from peak flow tests to help focus on effective treatment plans
    OBSTRUCTIVE SLEEP APNEA TESTS
    - Increased focus on diagnosis of sleep apnea at early stages to drive segment
    OTHER MECHANICAL TESTS
  • 7.3 IMAGING TESTS
    X-RAY
    - Increased investments in advanced radiographic technologies for superior lung imaging to drive segment
    COMPUTED TOMOGRAPHY
    - Growing focus on manufacturing high-resolution CT imaging for comprehensive respiratory assessments to drive segment
    MAGNETIC RESONANCE IMAGING
    - Rising investments in AI-enhanced MRI analysis for precise respiratory assessment to drive segment
    POSITRON EMISSION TOMOGRAPHY
    - Increased focus on effective treatment and management of lung cancer to drive segment
    OTHER IMAGING TESTS
  • 7.4 TRADITIONAL DIAGNOSTIC TESTS
    IMMUNODIAGNOSTICS
    - Increased focus on rapid disease diagnosis to drive segment
    BIOCHEMICAL CHARACTERIZATION
    - Rising number of collaborations among biochemical laboratories for developing advanced diagnostics to drive segment
    MICROSCOPY
    - Lack of sensitivity toward emerging diseases and potential virus bioterrorism to limit market
  • 7.5 MOLECULAR DIAGNOSTIC TESTS
    PCR
    - Development of portable, real-time PCR machines and assays to drive segment
    NUCLEIC ACID AMPLIFICATION
    - Growing focus on automated nucleic acid amplification processes to drive segment
    IN SITU HYBRIDIZATION
    - Increased adoption of automated technologies for streamlined respiratory testing to drive segment
    DNA SEQUENCING AND NEXT-GENERATION SEQUENCING
    - Rising number of research activities on sequencing-based biomarkers to drive segment
    MICROARRAYS
    - Easy and effective detection of genetic signatures across multiple genes to drive segment
    OTHER MOLECULAR DIAGNOSTIC TESTS
RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION
127
  • 8.1 INTRODUCTION
  • 8.2 TUBERCULOSIS
    INCREASING EARLY SCREENING PROGRAMS AND FUNDS BY GOVERNMENT TO DRIVE MARKET
  • 8.3 ASTHMA
    INCREASING AIR POLLUTION AND GROWING USE OF TOBACCO-BASED PRODUCTS TO DRIVE MARKET
  • 8.4 LUNG CANCER
    INCREASING NUMBER OF TOBACCO CONSUMERS TO DRIVE MARKET
  • 8.5 CHRONIC OBSTRUCTIVE PULMONARY DISEASE
    INCREASED INVESTMENT IN RESEARCH GRANTS FOR NOVEL BIOMARKERS AND DIAGNOSTIC TECHNOLOGIES TO DRIVE MARKET
  • 8.6 OTHER RESPIRATORY DISEASES
RESPIRATORY DIAGNOSTICS MARKET, BY END USER
134
  • 9.1 INTRODUCTION
  • 9.2 HOSPITALS AND CLINICS
    HOSPITALS AND CLINICS SEGMENT TO COMMAND LARGEST MARKET SHARE DURING STUDY PERIOD
  • 9.3 DIAGNOSTIC LABORATORIES
    EASY AND AFFORDABLE TESTING PROCESSES WITH TIMELY AND ACCURATE RESULTS TO DRIVE MARKET
  • 9.4 OTHER END USERS
RESPIRATORY DIAGNOSTICS MARKET, BY REGION
139
  • 10.1 INTRODUCTION
  • 10.2 NORTH AMERICA
    NORTH AMERICA: RECESSION IMPACT
    US
    - US to dominate North American respiratory diagnostics market during forecast period
    CANADA
    - Growing geriatric population and increasing awareness about early diagnosis of respiratory diseases to drive market
  • 10.3 EUROPE
    EUROPE: RECESSION IMPACT
    GERMANY
    - Increasing public healthcare expenditure to drive market
    FRANCE
    - Increasing prevalence of COPD and growing geriatric population to drive market
    UK
    - Rising number of hospitals and increasing government funding to drive market
    ITALY
    - Unfavorable reforms and reduction in healthcare expenditure by government to limit market
    SPAIN
    - Increasing healthcare spending and growing demand for home care services to drive market
    REST OF EUROPE
  • 10.4 ASIA PACIFIC
    ASIA PACIFIC: RECESSION IMPACT
    JAPAN
    - Availability of universal healthcare reimbursement policy and growth in geriatric population to drive market
    CHINA
    - Modern healthcare systems and improved reimbursement policies to drive market
    INDIA
    - Large patient population and availability of skilled medical professionals to drive market
    AUSTRALIA
    - Growing prevalence of chronic lung diseases to drive market
    SOUTH KOREA
    - Increasing geriatric population and rising disposable income to drive market
    REST OF ASIA PACIFIC
  • 10.5 LATIN AMERICA
    LATIN AMERICA: RECESSION IMPACT
    BRAZIL
    - Favorable healthcare initiatives by government to drive market
    MEXICO
    - Rising obesity rates and improving medical tourism to drive market
    REST OF LATIN AMERICA
  • 10.6 MIDDLE EAST & AFRICA
    GROWING PATIENT POPULATION AND INCREASING PENETRATION OF PRIVATE HEALTH INSURANCE COMPANIES TO DRIVE MARKET
    MIDDLE EAST & AFRICA: RECESSION IMPACT
COMPETITIVE LANDSCAPE
236
  • 11.1 OVERVIEW
  • 11.2 KEY STRATEGIES/RIGHT TO WIN
  • 11.3 REVENUE SHARE ANALYSIS
  • 11.4 MARKET SHARE ANALYSIS
  • 11.5 COMPANY EVALUATION MATRIX
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT
  • 11.6 START-UP/SME EVALUATION MATRIX
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING
  • 11.7 COMPETITIVE SCENARIOS AND TRENDS
    KEY PRODUCT LAUNCHES
    KEY DEALS
    OTHER KEY DEVELOPMENTS
COMPANY PROFILES
253
  • 12.1 KEY PLAYERS
    KONINKLIJKE PHILIPS N.V.
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    - MnM view
    BECTON, DICKINSON AND COMPANY
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    - MnM view
    ABBOTT
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    - MnM view
    THERMO FISHER SCIENTIFIC INC.
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    - MnM view
    GE HEALTHCARE
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    - MnM view
    BIO-RAD LABORATORIES, INC.
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    BIOMÉRIEUX
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    REVVITY, INC.
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    SEEGENE INC.
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    NIHON KOHDEN CORPORATION
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    VITALOGRAPH
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    SDI DIAGNOSTICS
    - Business overview
    - Products/Services/Solutions offered
    RESMED
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    SIEMENS HEALTHCARE GMBH
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    COSMED SRL
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    HOLOGIC, INC.
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    QIAGEN
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
  • 12.2 OTHER PLAYERS
    VYAIRE MEDICAL, INC.
    VISBY MEDICAL, INC.
    BRIOTA TECHNOLOGIES PVT. LTD.
    BIRD HEALTHCARE
    LÖWENSTEIN MEDICAL TECHNOLOGY GMBH
    PROAXSIS
    NDD MEDICAL TECHNOLOGIES
    COMPUMEDICS LIMITED
APPENDIX
329
  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 RISK ASSESSMENT: RESPIRATORY DIAGNOSTICS MARKET
  • TABLE 2 PREVALENCE OF LIFESTYLE DISEASES AND RELATED DEATHS
  • TABLE 3 TOP 10 COUNTRIES WITH HIGHEST NUMBER OF PRETERM BIRTHS, 2020
  • TABLE 4 INITIATIVES TO PROMOTE AWARENESS ABOUT ILL EFFECTS OF UNTREATED SLEEP APNEA
  • TABLE 5 US: CLASSIFICATION OF MEDICAL EQUIPMENT
  • TABLE 6 US: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 7 CANADA: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 8 EUROPE: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 9 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 10 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 11 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 TOP EXPORTERS OF RESPIRATORY DIAGNOSTICS DEVICES, 2022 (USD MILLION)
  • TABLE 15 MONITORING OF COPD PATIENTS AT HOME
  • TABLE 16 REPLACEMENT PATTERN OF VENTILATORS IN DEVELOPED ECONOMIES VS. EMERGING ECONOMIES
  • TABLE 17 VOLUME DATA OF VENTILATORS, ICU VENTILATORS, PORTABLE VENTILATORS, PAP DEVICES, CPAP DEVICES, BIPAP DEVICES, AND SPIROMETERS
  • TABLE 18 PORTER’S FIVE FORCES ANALYSIS
  • TABLE 19 LIST OF KEY CONFERENCES & EVENTS IN 2023–2024
  • TABLE 20 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
  • TABLE 21 KEY BUYING CRITERIA FOR RESPIRATORY DIAGNOSTIC DEVICES
  • TABLE 22 AVERAGE SELLING PRICE OF RESPIRATORY DIAGNOSTIC DEVICES, BY PRODUCT TYPE (USD)
  • TABLE 23 USE OF ARTIFICIAL INTELLIGENCE IN RESPIRATORY DIAGNOSTICS MARKET
  • TABLE 24 REIMBURSEMENT SCENARIO: RESPIRATORY DIAGNOSTICS MARKET
  • TABLE 25 RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION)
  • TABLE 26 RESPIRATORY DIAGNOSTICS MARKET FOR INSTRUMENTS AND DEVICES, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 27 RESPIRATORY DIAGNOSTICS MARKET FOR ASSAYS AND REAGENTS, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 28 RESPIRATORY DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 29 RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
  • TABLE 30 RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 31 RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 32 PULMONARY FUNCTION TESTS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 33 PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 34 SPIROMETRY TESTS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 35 PEAK FLOW TESTS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 36 OBSTRUCTIVE SLEEP APNEA TESTS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 37 OTHER MECHANICAL TESTS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 38 RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 39 RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 40 X-RAY MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 41 COMPUTED TOMOGRAPHY MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 42 MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 43 POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 44 OTHER IMAGING TESTS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 45 RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 46 RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 47 IMMUNODIAGNOSTICS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 48 BIOCHEMICAL CHARACTERIZATION MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 49 MICROSCOPY MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 50 RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTIC TESTS, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 51 RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 52 PCR MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 53 NUCLEIC ACID AMPLIFICATION MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 54 IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 55 DNA SEQUENCING AND NEXT GENERATION SEQUENCING MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 56 MICROARRAYS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 57 OTHER MOLECULAR DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 58 RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION)
  • TABLE 59 RESPIRATORY DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 60 RESPIRATORY DIAGNOSTICS MARKET FOR ASTHMA, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 61 RESPIRATORY DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 62 RESPIRATORY DIAGNOSTICS MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 63 RESPIRATORY DIAGNOSTICS MARKET FOR OTHER RESPIRATORY DISEASES, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 64 RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 65 RESPIRATORY DIAGNOSTICS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 66 RESPIRATORY DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 67 RESPIRATORY DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 68 RESPIRATORY DIAGNOSTICS MARKET, BY REGION, 2021–2029 (USD MILLION)
  • TABLE 69 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 70 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION)
  • TABLE 71 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
  • TABLE 72 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 73 NORTH AMERICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 74 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 75 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 76 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 77 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION)
  • TABLE 78 NORTH AMERICA RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 79 US: KEY MACROINDICATORS
  • TABLE 80 US: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION)
  • TABLE 81 US: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
  • TABLE 82 US: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 83 US: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 84 US: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 85 US: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 86 US: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 87 US: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION)
  • TABLE 88 US: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 89 CANADA: COPD AND ASTHMA STATISTICS (2019 VS. 2020)
  • TABLE 90 CANADA: KEY MACROINDICATORS
  • TABLE 91 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION)
  • TABLE 92 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
  • TABLE 93 CANADA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 94 CANADA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 95 CANADA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 96 CANADA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 97 CANADA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 98 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION)
  • TABLE 99 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 100 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 101 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION)
  • TABLE 102 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
  • TABLE 103 EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 104 EUROPE: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 105 EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 106 EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 107 EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 108 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION)
  • TABLE 109 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 110 GERMANY: KEY MACROINDICATORS
  • TABLE 111 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION)
  • TABLE 112 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
  • TABLE 113 GERMANY: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 114 GERMANY: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 115 GERMANY: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 116 GERMANY: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 117 GERMANY: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 118 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION)
  • TABLE 119 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 120 FRANCE: KEY MACROINDICATORS
  • TABLE 121 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION)
  • TABLE 122 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
  • TABLE 123 FRANCE: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 124 FRANCE: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 125 FRANCE: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 126 FRANCE: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 127 FRANCE: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 128 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION)
  • TABLE 129 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 130 UK: KEY MACROINDICATORS
  • TABLE 131 UK: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION)
  • TABLE 132 UK: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
  • TABLE 133 UK: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 134 UK: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 135 UK: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 136 UK: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 137 UK: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 138 UK: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION)
  • TABLE 139 UK: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 140 ITALY: KEY MACROINDICATORS
  • TABLE 141 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION)
  • TABLE 142 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
  • TABLE 143 ITALY: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 144 ITALY: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 145 ITALY: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 146 ITALY: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 147 ITALY: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 148 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION)
  • TABLE 149 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 150 SPAIN: KEY MACROINDICATORS
  • TABLE 151 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION)
  • TABLE 152 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
  • TABLE 153 SPAIN: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 154 SPAIN: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 155 SPAIN: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 156 SPAIN: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 157 SPAIN: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 158 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION)
  • TABLE 159 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 160 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION)
  • TABLE 161 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
  • TABLE 162 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 163 REST OF EUROPE: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 164 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 165 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 166 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 167 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION)
  • TABLE 168 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 169 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 170 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION)
  • TABLE 171 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
  • TABLE 172 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 173 ASIA PACIFIC: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 174 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 175 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 176 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 177 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION)
  • TABLE 178 ASIA PACIFIC RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 179 JAPAN: KEY MACROINDICATORS
  • TABLE 180 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION)
  • TABLE 181 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
  • TABLE 182 JAPAN: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 183 JAPAN: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 184 JAPAN: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 185 JAPAN: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 186 JAPAN: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 187 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION)
  • TABLE 188 JAPAN RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 189 CHINA: KEY MACROINDICATORS
  • TABLE 190 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION)
  • TABLE 191 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
  • TABLE 192 CHINA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 193 CHINA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 194 CHINA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 195 CHINA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 196 CHINA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 197 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION)
  • TABLE 198 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 199 INDIA: KEY MACROINDICATORS
  • TABLE 200 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION)
  • TABLE 201 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
  • TABLE 202 INDIA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 203 INDIA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 204 INDIA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 205 INDIA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 206 INDIA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 207 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION)
  • TABLE 208 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 209 AUSTRALIA: KEY MACROINDICATORS
  • TABLE 210 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION)
  • TABLE 211 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
  • TABLE 212 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 213 AUSTRALIA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 214 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 215 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 216 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 217 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION)
  • TABLE 218 AUSTRALIA RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 219 SOUTH KOREA: KEY MACROINDICATORS
  • TABLE 220 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION)
  • TABLE 221 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
  • TABLE 222 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 223 SOUTH KOREA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 224 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 225 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 226 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 227 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION)
  • TABLE 228 SOUTH KOREA RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 229 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION)
  • TABLE 230 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
  • TABLE 231 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 232 REST OF ASIA PACIFIC: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 233 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 234 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 235 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 236 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION)
  • TABLE 237 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 238 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 239 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION)
  • TABLE 240 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
  • TABLE 241 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 242 LATIN AMERICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 243 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 244 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 245 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 246 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION)
  • TABLE 247 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 248 BRAZIL: KEY MACROINDICATORS
  • TABLE 249 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION)
  • TABLE 250 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
  • TABLE 251 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 252 BRAZIL: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 253 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 254 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 255 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 256 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION)
  • TABLE 257 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 258 MEXICO: KEY MACROINDICATORS
  • TABLE 259 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION)
  • TABLE 260 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
  • TABLE 261 MEXICO: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 262 MEXICO: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 263 MEXICO: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 264 MEXICO: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 265 MEXICO: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 266 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION)
  • TABLE 267 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 268 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION)
  • TABLE 269 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
  • TABLE 270 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 271 REST OF LATIN AMERICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 272 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 273 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 274 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 275 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION)
  • TABLE 276 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 277 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION)
  • TABLE 278 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
  • TABLE 279 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 280 MIDDLE EAST & AFRICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 281 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 282 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 283 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 284 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION)
  • TABLE 285 MIDDLE EAST & AFRICA RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 286 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS IN RESPIRATORY DIAGNOSTICS MARKET
  • TABLE 287 PRODUCT AND SERVICE FOOTPRINT
  • TABLE 288 TEST TYPE FOOTPRINT
  • TABLE 289 END USER FOOTPRINT
  • TABLE 290 REGIONAL FOOTPRINT
  • TABLE 291 OVERALL COMPANY FOOTPRINT
  • TABLE 292 KEY PRODUCT LAUNCHES, 2021–2023
  • TABLE 293 KEY DEALS, 2021–2023
  • TABLE 294 OTHER KEY DEVELOPMENTS, 2021–2023
  • TABLE 295 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW
  • TABLE 296 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
  • TABLE 297 ABBOTT: COMPANY OVERVIEW
  • TABLE 298 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 299 GE HEALTHCARE: COMPANY OVERVIEW
  • TABLE 300 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
  • TABLE 301 BIOMÉRIEUX: COMPANY OVERVIEW
  • TABLE 302 REVVITY, INC.: COMPANY OVERVIEW
  • TABLE 303 SEEGENE INC.: COMPANY OVERVIEW
  • TABLE 304 NIHON KOHDEN CORPORATION: COMPANY OVERVIEW
  • TABLE 305 VITALOGRAPH: COMPANY OVERVIEW
  • TABLE 306 SDI DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 307 RESMED: COMPANY OVERVIEW
  • TABLE 308 SIEMENS HEALTHCARE GMBH: COMPANY OVERVIEW
  • TABLE 309 COSMED SRL: COMPANY OVERVIEW
  • TABLE 310 HOLOGIC, INC.: COMPANY OVERVIEW
  • TABLE 311 QIAGEN: COMPANY OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 RESEARCH DESIGN
  • FIGURE 2 PRIMARY SOURCES
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY END USER, DESIGNATION, AND REGION
  • FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 6 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
  • FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION: KONINKLIJKE PHILIPS N.V.
  • FIGURE 8 SUPPLY-SIDE ANALYSIS: RESPIRATORY DIAGNOSTICS MARKET (2022)
  • FIGURE 9 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 11 TOP-DOWN APPROACH
  • FIGURE 12 MARKET DATA TRIANGULATION METHODOLOGY
  • FIGURE 13 RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2023 VS. 2029 (USD MILLION)
  • FIGURE 14 RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2023 VS. 2029 (USD MILLION)
  • FIGURE 15 RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2023 VS. 2029 (USD MILLION)
  • FIGURE 16 RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2029 (USD MILLION)
  • FIGURE 17 GEOGRAPHICAL SNAPSHOT OF RESPIRATORY DIAGNOSTICS MARKET
  • FIGURE 18 TECHNOLOGICAL ADVANCEMENTS AND GROWTH IN GERIATRIC POPULATION TO DRIVE MARKET
  • FIGURE 19 NORTH AMERICA COMMANDED LARGEST MARKET SHARE IN 2022
  • FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 21 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING STUDY PERIOD
  • FIGURE 22 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES: RESPIRATORY DIAGNOSTICS MARKET
  • FIGURE 23 GLOBAL GERIATRIC POPULATION, BY REGION
  • FIGURE 24 PERCENTAGE OF DEATHS CAUSED BY HOUSEHOLD AND AMBIENT AIR POLLUTION, BY DISEASE (APPROXIMATELY, EVERY YEAR)
  • FIGURE 25 PRETERM BIRTH BY GESTATIONAL AGE AND REGION, 2020
  • FIGURE 26 SUPPLY CHAIN ANALYSIS: RESPIRATORY DIAGNOSTICS MARKET
  • FIGURE 27 ECOSYSTEM MARKET MAP: RESPIRATORY DIAGNOSTICS MARKET
  • FIGURE 28 VALUE CHAIN ANALYSIS: RESPIRATORY DIAGNOSTICS MARKET
  • FIGURE 29 PATENT PUBLICATION TRENDS, 2013–2023
  • FIGURE 30 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR RESPIRATORY DIAGNOSTIC PATENTS (JANUARY 2013–NOVEMBER 2023)
  • FIGURE 31 TOP APPLICANT COUNTRIES/REGIONS FOR RESPIRATORY DIAGNOSTIC PATENTS (JANUARY 2013–NOVEMBER 2023)
  • FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR RESPIRATORY DIAGNOSTIC DEVICES
  • FIGURE 33 KEY BUYING CRITERIA FOR RESPIRATORY DIAGNOSTIC DEVICES
  • FIGURE 34 ADJACENT MARKETS OF RESPIRATORY DIAGNOSTICS MARKET
  • FIGURE 35 RESPIRATORY DIAGNOSTICS MARKET REGIONAL SNAPSHOT
  • FIGURE 36 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 37 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 38 RESPIRATORY DIAGNOSTICS REVENUE SHARE ANALYSIS FOR MECHANICAL, TRADITIONAL, AND MOLECULAR TESTS, BY KEY PLAYER, 2018–2022 (USD MILLION)
  • FIGURE 39 RESPIRATORY DIAGNOSTICS REVENUE SHARE ANALYSIS FOR IMAGING TESTS, BY KEY PLAYER, 2018–2022 (USD MILLION)
  • FIGURE 40 RESPIRATORY DIAGNOSTICS MARKET SHARE FOR MECHANICAL, TRADITIONAL, AND MOLECULAR TESTS, BY KEY PLAYER, 2022
  • FIGURE 41 RESPIRATORY DIAGNOSTICS MARKET SHARE ANALYSIS FOR IMAGING TESTS, BY KEY PLAYER, 2022
  • FIGURE 42 COMPANY EVALUATION MATRIX, 2022
  • FIGURE 43 START-UP/SME EVALUATION MATRIX, 2022
  • FIGURE 44 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2022)
  • FIGURE 45 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
  • FIGURE 46 ABBOTT: COMPANY SNAPSHOT (2022)
  • FIGURE 47 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
  • FIGURE 48 GE HEALTHCARE: COMPANY SNAPSHOT (2022)
  • FIGURE 49 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
  • FIGURE 50 BIOMÉRIEUX: COMPANY SNAPSHOT (2022)
  • FIGURE 51 PERKINELMER INC.: COMPANY SNAPSHOT (2022)
  • FIGURE 52 SEEGENE INC.: COMPANY SNAPSHOT (2022)
  • FIGURE 53 NIHON KOHDEN CORPORATION: COMPANY SNAPSHOT (2022)
  • FIGURE 54 RESMED: COMPANY SNAPSHOT (2022)
  • FIGURE 55 SIEMENS HEALTHCARE GMBH: COMPANY SNAPSHOT (2022)
  • FIGURE 56 HOLOGIC, INC.: COMPANY SNAPSHOT (2022)
  • FIGURE 57 QIAGEN: COMPANY SNAPSHOT (2022)

The market size for respiratory diagnostics market was estimated using four main methods in this study. The market, as well as its peer and parent markets, were the subject of extensive research. The subsequent phase involved doing primary research to confirm these conclusions, presumptions, and estimates with industry professionals across the value chain. For estimating the value market, top-down and bottom-up strategies were both used. The market size of segments and subsegments was then estimated using market breakdown and data triangulation processes.

Secondary Research

There were several secondary sources used in this study, including directories, databases like Bloomberg Business, Factiva, and Dun & Bradstreet, white papers, annual reports, corporate house documents, investor presentations, and firm SEC filings. To find and gather data for the detailed, technical, market-focused, and commercial analysis of the respiratory diagnostics market, secondary research was carried out. Relevant information on major companies, market classification and segmentation according to industry trends down to the most basic level, and significant changes regarding market and technological views were also obtained. Additionally, utilizing secondary research, a database of the important industry executives was created.

Primary Research

To gather qualitative and quantitative data for this study, a variety of sources from the supply and demand sides were interviewed during the main research phase. CEOs, vice presidents, marketing and sales directors, business development managers, technology, and innovation directors of respiratory diagnostics market manufacturing businesses, key opinion leaders, suppliers, and distributors are the main sources on the supply side.

Breakdown of Primary Interviews

Respiratory diagnostics market Size, and Share

Tiers are defined based on a company’s total revenue. As of 2022: Tier 1= >USD 2 billion, Tier 2 = USD 50 million to USD 2 billion, and Tier 3= <USD 50 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The market size for respiratory diagnostics market was calculated using data from four different sources, as will be discussed below. Each technique concluded and a weighted average of the four ways was calculated based on the number of assumptions each approach made. The market size for respiratory diagnostics market was calculated using data from four distinct sources, as will be discussed below:

Respiratory diagnostics market: Bottom up approach

Respiratory diagnostics market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Respiratory diagnostics market: Top down approach

Respiratory diagnostics market Size, and Share

Respiratory diagnostics market: Revenue Share Analysis

Respiratory diagnostics market Size, and Share

Respiratory diagnostics market: Supply side analysis of top companies

Respiratory diagnostics market Size, and Share

Data Triangulation

The entire market was split up into several segments when the market size was determined. Data triangulation and market breakdown processes were used where necessary to complete the entire market engineering process and arrive at the precise statistics for all segments.

Approach to derive the market size and estimate market growth

Using secondary data from both paid and unpaid sources, the market rankings for the major players were determined following a thorough analysis of their sales of respiratory diagnostics. Due to data restrictions, the revenue share in certain cases was determined after a thorough analysis of the product portfolio of big corporations and their individual sales performance. This information was verified at each stage by in-depth interviews with professionals in the field.

Market Definition

Respiratory diagnostic devices are used to assess and monitor the functioning of the respiratory system. These devices play a crucial role in diagnosing and managing various respiratory conditions. They include a wide range of equipment designed to aid in breathing, improve pulmonary function, and assist in the removal of mucus from the airways. Some of the respiratory diagnostic tests include mechanical tests like Spirometry, Pulse Oximetry, Bronchoscopy, Diagnostic Imaging tests, and In vitro diagnostic tests.

Key Stakeholders

  • Respiratory diagnostic device manufacturers and distributors
  • Healthcare institutions (hospitals, laboratories, medical schools, and outpatient clinics)
  • Research institutes
  • Contract manufacturing organizations (CMOs)
  • Government associations
  • Market research and consulting firms
  • Venture capitalists and investors
  • Market research and consulting firms

Objectives of the Study

  • To define, describe, and forecast the respiratory diagnostics market by product and service, test type, disease indication, end user, and region.
  • To provide detailed information about the key factors influencing the market growth, such as drivers, restraints, opportunities, challenges, and industry trends
  • To strategically analyze the regulatory scenario, Porter’s five force analysis, value chain analysis, supply chain analysis, ecosystem map, recession impact, and patent analysis
  • To analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall respiratory diagnostics market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.
  • To strategically profile the key players in this market and comprehensively analyze their market shares and core competencies2
  • To strategically analyze the respiratory diagnostics market in five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To track and analyze competitive developments such as acquisitions, product launches, partnerships, and expansions in the respiratory diagnostics market.
  • To evaluate the impact of the recession on the respiratory diagnostics market market worldwide.
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
MD 4740
Published ON
Nov, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Respiratory Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
knowledgestore logo

Hold On!

Want to explore hidden markets that can drive new revenue in Respiratory Diagnostics Market?

Find Hidden Markets
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status
Website Feedback